Clinical Trial

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it
Protocol Amendment History 1 change
notable Trial sites expanded: 78 -> 81 locations 2026-05-13
Trial Details
NCT Number NCT07044297
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Enrollment 4,390 participants
Start Date 2025-07-31
Primary Completion 2027-07-22 (estimated)
Study Completion 2027-07-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-14